SELECT-GCA: Upadacitinib in Giant Cell Arteritis

preview_player
Показать описание
Dr. Mike Putman reports on abstract 0770, Efficacy and Safety of Upadacitinib in Patients with Giant Cell Arteritis (SELECT-GCA): A Double-Blind, Randomized Controlled Phase 3 Trial, presented at the 2024 ACR Convergence meeting in Washington, DC.
  1. RheumNow
  2. Rheumatoid
  3. arthritis
  4. Rheumatology
  5. Lupus
  6. Vasculitis
Рекомендации по теме
SELECT-GCA: Upadacitinib in 0:03:02

SELECT-GCA: Upadacitinib in Giant Cell Arteritis

SELECTing the right 0:05:20

SELECTing the right patients: upadacitinib in GCA

SELECT-GCA: Efficacy and 0:04:20

SELECT-GCA: Efficacy and Safety of Upadacitinib

Adding Upadacitinib to 0:08:46

Adding Upadacitinib to the Treatment Landscape of GCA, with Daniel Blockmans, MD, PhD

Giant Cell Arteritis 0:04:16

Giant Cell Arteritis Just Got a Pill—Here’s the Science

Author Interview: Professor 0:26:44

Author Interview: Professor Daniel Blockmans, 2024

GCA and Current 1:00:08

GCA and Current Clinical Trials

Advances in the 1:01:10

Advances in the treatment of giant-cell arteritis (ERN-RITA Webinar)

Updates in Large 0:59:20

Updates in Large Vessel Vasculitis

The Expanding Role 0:36:51

The Expanding Role of JAK Inhibitors Across IMIDs

Artérite à cellules 1:17:30

Artérite à cellules géantes. Actualisation diagnostique et thérapeutique

Management Of Rheumatic 1:27:50

Management Of Rheumatic & Musculoskeletal Diseases

4th Ain Shams 1:13:35

4th Ain Shams Rheumatology & Immunology congress | Day 1 | Session 3

T2T arteritis de 1:07:26

T2T arteritis de células gigantes y polimialgia reumática. Dr Carlos Toro

welcome to shbcf.ru